Literature DB >> 22895158

Dry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006.

Anat Galor1, D Diane Zheng, Kristopher L Arheart, Byron L Lam, Victor L Perez, Kathryn E McCollister, Manuel Ocasio, Laura A McClure, David J Lee.   

Abstract

PURPOSE: To study dry eye medication use and expenditures from 2001 to 2006 using a nationally representative sample of US adults.
METHODS: This study retrospectively analyzed dry eye medication use and expenditures of participants of the 2001 to 2006 Medical Expenditure Panel Survey, a nationally representative subsample of the National Health Interview Survey. After adjusting for survey design and for inflation using the 2009 inflation index, data from 147 unique participants aged 18 years or older using the prescription medications Restasis and Blephamide were analyzed. The main outcome measures were dry eye medication use and expenditures from 2001 to 2006.
RESULTS: Dry eye medication use and expenditures increased between the years 2001 and 2006, with the mean expenditure per patient per year being $55 in 2001 to 2002 (n=29), $137 in 2003 to 2004 (n=32), and $299 in 2005 to 2006 (n=86). This finding was strongly driven by the introduction of topical cyclosporine emulsion 0.05% (Restasis; Allergan, Irvine, CA). In analysis pooled over all survey years, demographic factors associated with dry eye medication expenditures included gender (female: $244 vs. male: $122, P<0.0001), ethnicity (non-Hispanic: $228 vs. Hispanic: $106, P<0.0001), and education (greater than high school: $250 vs. less than high school: $100, P<0.0001).
CONCLUSIONS: We found a pattern of increasing dry eye medication use and expenditures from 2001 to 2006. Predictors of higher dry eye medication expenditures included female gender, non-Hispanic ethnicity, and greater than a high school education.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895158     DOI: 10.1097/ICO.0b013e31823cc0b7

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  21 in total

Review 1.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

2.  Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence.

Authors:  Philip Ames; Anat Galor
Journal:  Clin Investig (Lond)       Date:  2015

3.  Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.

Authors:  Serkan Ozen; Murat Atabey Ozer; Mehmet Orçun Akdemir
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-15       Impact factor: 3.117

Review 4.  Neuropathic ocular pain: an important yet underevaluated feature of dry eye.

Authors:  A Galor; R C Levitt; E R Felix; E R Martin; C D Sarantopoulos
Journal:  Eye (Lond)       Date:  2014-11-07       Impact factor: 3.775

5.  Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane.

Authors:  Anny M S Cheng; Dandan Zhao; Rendian Chen; Han Y Yin; Sean Tighe; Hosam Sheha; Victoria Casas; Scheffer C G Tseng
Journal:  Ocul Surf       Date:  2015-09-24       Impact factor: 5.033

Review 6.  Burning Eye Syndrome: Do Neuropathic Pain Mechanisms Underlie Chronic Dry Eye?

Authors:  Jerry P Kalangara; Anat Galor; Roy C Levitt; Elizabeth R Felix; Ramon Alegret; Constantine D Sarantopoulos
Journal:  Pain Med       Date:  2015-12-24       Impact factor: 3.750

Review 7.  Image-guided evaluation and monitoring of treatment response in patients with dry eye disease.

Authors:  Yureeda Qazi; Shruti Aggarwal; Pedram Hamrah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-04       Impact factor: 3.117

8.  Ophthalmic Medication Expenditures and Out-of-Pocket Spending: An Analysis of United States Prescriptions from 2007 through 2016.

Authors:  Evan M Chen; Ninani Kombo; Christopher C Teng; Prithvi Mruthyunjaya; Kristen Nwanyanwu; Ravi Parikh
Journal:  Ophthalmology       Date:  2020-04-28       Impact factor: 14.277

Review 9.  Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature.

Authors:  Michelle K Rhee; Francis S Mah
Journal:  Clin Ophthalmol       Date:  2017-06-21

10.  Social-economic analysis of patients with Sjogren's syndrome dry eye in East China: a cross-sectional study.

Authors:  Wang Yao; Qihua Le
Journal:  BMC Ophthalmol       Date:  2018-02-02       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.